News & Updates

Real Endpoints Recent Developments

‘DrugAbacus’, a Comparative Cancer Drug Pricing Platform Powered by Real Endpoints’ RxScorecard™, is Launched

Posted by Julie Eagle on Friday, June 19, 2015

Westport, CT, June 19, 2015 – Real Endpoints (RE) is pleased to announce that its RxScorecard™ is the information technology platform supporting Memorial Sloan Kettering Cancer Center’s DrugAbacus – an interactive tool for considering the basis of cancer drug...

Learn More

Wall Street Journal publishes article on new cancer pricing tool from Memorial Sloan Kettering using RE’s RxScorecard technology

Posted by Julie Eagle on Friday, June 19, 2015

June 19, 2015 – Memorial Sloan Kettering Cancer Center, one of the nation’s top cancer hospitals, has created an interactive calculator that compares the cost of more than 50 cancer drugs with what the prices would be if they were tied to factors such as...

Learn More

ASCO accepts Real Endpoints’ abstract on RxScorecard analysis of adjuvant breast cancer therapies

Posted by Julie Eagle on Thursday, May 14, 2015

Real Endpoints is pleased to announce that it will be presenting its RxScorecard on adjuvant breast cancer at ASCO’s annual meeting in June. The analysis demonstrates that its RxScorecard interactive, web-based tool can determine relative drug value using weighted...

Learn More

BioCenturyTV Interviews Real Endpoints CEO on Determining Value in Specialty Drugs

Posted by Julie Eagle on Tuesday, December 9, 2014

BioCentury TV Interviews Roger Longman, CEO of Real Endpoints as part of a series on the high cost of drugs.  In Part I, Longman addresses the importance of valuing drug therapy. In his second interview, Longman discusses the changing trajectory for specialty drugs....

Learn More

We Need More Transparency on the Cost of Specialty Drugs

Posted by Julie Eagle on Friday, November 7, 2014

Harvard Business Review, November 4, 2014 We Need More Transparency on the Cost of Specialty Drugs, by Robert Galvin, MD and Roger Longman Decisions about which drugs to include in and exclude from formularies are part of a larger problem. As a society, we have...

Learn More

Move over Gilead? AbbVie could bring serious competition to HCV market.

Posted by Julie Eagle on Monday, October 13, 2014

Gilead’s Harvoni might be the top overall performer, says RxScorecard™, but a discounted Triple regimen from AbbVie could mount major challenge. Gilead’s Harvoni (sofosbuvir/ledipasvir combination) is the top overall scorer, according to RxScorecard, a drug-value...

Learn More